Augustine Therapeutics
New York, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $84.8M
Overview
A preclinical biotech developing novel small molecules to modify the course of neurodegenerative diseases like Alzheimer's and ALS.
NeuroscienceNeurodegenerative Diseases
Technology Platform
Proprietary platform targeting novel neuronal stress and survival pathways to discover disease-modifying small molecules for neurodegeneration.
Funding History
1Total raised:$84.8M
PIPE$84.8M
Opportunities
A breakthrough therapy in Alzheimer's or ALS represents one of the largest unmet medical needs and potential blockbuster markets in biopharma.
Risk Factors
Extreme risk of preclinical and clinical failure due to the poor historical success rate and incomplete understanding of neurodegenerative disease biology.
Competitive Landscape
Operates in the high-risk, high-reward neurodegenerative space against large pharma and numerous biotechs, many pursuing similar disease-modifying goals.